GSK and Ranbaxy to collaborate on drug discovery and development
GlaxoSmithKline has entered into a drug discovery and clinical development collaboration with India's largest pharmaceutical manufacturer Ranbaxy Laboratories. The agreement will cover a wide range of therapeutic areas.
GlaxoSmithKline has entered into a drug discovery and clinical development collaboration with India's largest pharmaceutical manufacturer Ranbaxy Laboratories. The agreement will cover a wide range of therapeutic areas.
Several collaborative scenarios are envisioned, with GSK and Ranbaxy leveraging their respective resources and expertise. Ranbaxy will be responsible for activities from optimisation of a lead compound to generation of a development candidate. Leads may be provided by either GSK or Ranbaxy. For a proportion of the candidates selected within the collaboration, it is expected that Ranbaxy will conduct early clinical work. GSK and Ranbaxy will form an executive steering committee to oversee the research.
Once a compound has been selected as a development candidate, in most instances GSK will complete development. GSK will have the exclusive commercialisation responsibilities worldwide, while Ranbaxy will take the lead in India.
'This collaboration provides an avenue to Ranbaxy to leverage its discovery and early product development strengths and gain access to cutting edge technologies,' said Dr Rashmi Barbhaiya, president, research & development, Ranbaxy.